Sep 6 |
Who Can Use the New Obesity Drugs? Nearly Half of Adults Under 65 Are Eligible.
|
Sep 6 |
Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More
|
Sep 6 |
Nvidia And Apple Get The Glory. This Snubbed Stock Gets The Money.
|
Sep 6 |
This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem
|
Sep 6 |
Lilly’s efsitora shows promise in Phase III type 2 diabetes trials
|
Sep 5 |
Eli Lilly bets $409M for AI-focused drug discovery
|
Sep 5 |
Eli Lilly and Company (LLY) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
|
Sep 5 |
Lilly partners with Haya for lncRNA obesity target deal worth $1bn
|
Sep 5 |
Eli Lilly Makes Strides on Weekly Insulin Shot as Novo Nordisk Stumbles
|
Sep 5 |
Eli Lilly's Once-Weekly Insulin Shows Non-Inferior Blood Sugar Reduction Vs Frequently Used Daily Insulins In Long Term Trials
|